Racemization and enantiomer separation of clopidogrel
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsMerli Valeriano, Paola Daverio, Stefano Bianchi
Life of this patent
Estimating the term…
Abstract
Processes for separation of enantiomers of clopidogrel, and converting one enantiomer of clopidogrel to another enantiomer of clopidogrel are provided. The enantiomers are separated by crystallizing the (S) enantiomer as camphor sulfonate salt from a hydrocarbon, or a mixture of a hydrocarbon and a co-solvent, preferably DMF:toluene. The (R) enantiomer is then racemized and recycled by reaction with a catalytic amount of a base, preferably with t-butoxide.
Claims20
A process for preparing (S) clopidogrel free base or a pharmaceutically acceptable salt thereof comprising the steps of:
- a) reacting a mixture of (R) and (S) clopidogrel free base with levorotatory camphor sulfonic acid in a mixture of a C5 to a C12 hydrocarbon and a suitable co-solvent to precipitate (S) clopidogrel camphor sulfonate;
- and
- b) converting (S) clopidogrel camphor sulfonate to clopidogrel free base or a pharmaceutically acceptable salt thereof.
A process for racemizing (R) clopidogrel comprising reacting (R) clopidogrel with a catalytic amount of a base in a solvent to convert a portion of the (R) clopidogrel to (S) clopidogrel.
Dependencies are inferred from the claim text.